S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
S&P 500   3,136.63 (+0.02%)
DOW   27,903.39 (-0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.43 (+0.94%)
FB   200.99 (-0.17%)
MSFT   151.54 (+0.12%)
GOOGL   1,345.01 (+0.15%)
AMZN   1,741.09 (-0.48%)
NVDA   215.00 (+1.33%)
MU   47.70 (+2.67%)
BABA   201.29 (+1.28%)
GE   11.00 (+0.00%)
TSLA   349.81 (+3.03%)
T   38.20 (+0.42%)
AMD   39.69 (+1.95%)
F   9.09 (+0.89%)
PRI   135.36 (+0.00%)
NFLX   297.53 (-1.64%)
BAC   33.49 (-0.06%)
GILD   66.96 (+0.04%)
Log in

NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Forecast & News

$6.24
+0.03 (+0.48 %)
(As of 12/10/2019 01:12 PM ET)
Today's Range
$6.20
Now: $6.24
$6.27
50-Day Range
$6.08
MA: $6.25
$6.46
52-Week Range
$1.29
Now: $6.24
$6.46
Volume313,461 shs
Average Volume1.51 million shs
Market Capitalization$873.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15 million
Book Value$1.92 per share

Profitability

Net Income$-70,270,000.00

Miscellaneous

Employees56
Market Cap$873.91 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.


Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.02. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

5 analysts have issued twelve-month price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they expect Achillion Pharmaceuticals' share price to reach $5.03 in the next year. This suggests that the stock has a possible downside of 19.3%. View Analyst Price Targets for Achillion Pharmaceuticals.

What is the consensus analysts' recommendation for Achillion Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Has Achillion Pharmaceuticals been receiving favorable news coverage?

News coverage about ACHN stock has trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Achillion Pharmaceuticals.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 8,950,000 shares, an increase of 11.5% from the September 15th total of 8,030,000 shares. Based on an average trading volume of 2,990,000 shares, the short-interest ratio is currently 3.0 days. Approximately 6.6% of the shares of the company are sold short. View Achillion Pharmaceuticals' Current Options Chain.

Who are some of Achillion Pharmaceuticals' key competitors?

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD), Edap Tms (EDAP) and Celldex Therapeutics (CLDX).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph Truitt, Pres, CEO & Director (Age 54)
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 64)
  • Mr. Brian R. Di Donato, CFO, SVP & Treasurer (Age 52)
  • Mr. Paul Firuta, Exec. VP & COO (Age 53)
  • Dr. Kevin P. Malobisky, Sr. VP of Regulatory Affairs, Quality & Compliance

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (3.21%), Millennium Management LLC (2.35%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.19%), Rhumbline Advisers (0.16%) and California Public Employees Retirement System (0.15%). Company insiders that own Achillion Pharmaceuticals stock include David Scheer and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which major investors are selling Achillion Pharmaceuticals stock?

ACHN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, SG Americas Securities LLC and Alps Advisors Inc.. Company insiders that have sold Achillion Pharmaceuticals company stock in the last year include David Scheer and Joseph Truitt. View Insider Buying and Selling for Achillion Pharmaceuticals.

Which major investors are buying Achillion Pharmaceuticals stock?

ACHN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, California Public Employees Retirement System, Bourgeon Capital Management LLC, Rhumbline Advisers, Meeder Asset Management Inc., Virtu Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $6.24.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $873.91 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

What is Achillion Pharmaceuticals' official website?

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  480 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  898
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Support Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel